Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Javier Ampudia-Blasco

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Medicina Clinica|January 22, 2014
[Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes]Olga González Albarrán, F Javier Ampudia-Blasco
Diabetes Technology & Therapeutics|June 15, 2011
Basal plus basal-bolus approach in type 2 diabetesF Javier Ampudia-Blasco, Paolo Rossetti, Juan F Ascaso
Diabetes Care|January 21, 2022
Real-world Evidence of Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Therapy in Adults With Type 1 Diabetes: A European Two-Center ExperienceAna Palanca, Falco van Nes, Felipe Pardo, et al.
Human Vaccines & Immunotherapeutics|September 22, 2017
Risk and impact of herpes zoster on patients with diabetes: A population-based study, 2009-2014Cintia Muñoz-Quiles, Mónica López-Lacort, F Javier Ampudia-Blasco, et al.
Diabetes Research and Clinical Practice|June 22, 2019
How often patients on insulin therapy measure postprandial glycemia and modify insulin doses accordingly? From an on-line survey in insulin-treated diabetes patients in SpainEdurne Lecumberri Pascual, Cristina Tejera Pérez, Araceli Muñoz-Garach, et al.
European Journal of Clinical Investigation|March 21, 2022
Impact of COVID-19 lockdown on diabetes management and follow-up in a broad population in SpainAna Palanca, Carmen Quinones-Torrelo, Juan Girbés, et al.
Journal of Diabetes and Its Complications|January 13, 2021
Therapeutic inertia in patients with type 2 diabetes treated with non-insulin agentsF Javier Ampudia-Blasco, Ana Palanca, Jose Luis Trillo, et al.
Diabetes Technology & Therapeutics|September 26, 2012
Evaluation of a novel continuous glucose monitoring-based method for mealtime insulin dosing--the iBolus--in subjects with type 1 diabetes using continuous subcutaneous insulin infusion therapy: a randomized controlled trialPaolo Rossetti, F Javier Ampudia-Blasco, Alejandro Laguna, et al.
Pharmacoeconomics|June 28, 2006
Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in SpainArran T Shearer, Adrian Bagust, F Javier Ampudia-Blasco, et al.
Diabetes, Obesity & Metabolism|July 6, 2018
Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetesJulio Rosenstock, Yehuda Handelsman, Josep Vidal, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Medicina Clinica|January 22, 2014
[Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes]Olga González Albarrán, F Javier Ampudia-Blasco
Diabetes Technology & Therapeutics|June 15, 2011
Basal plus basal-bolus approach in type 2 diabetesF Javier Ampudia-Blasco, Paolo Rossetti, Juan F Ascaso
Diabetes Care|January 21, 2022
Real-world Evidence of Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Therapy in Adults With Type 1 Diabetes: A European Two-Center ExperienceAna Palanca, Falco van Nes, Felipe Pardo, et al.
Human Vaccines & Immunotherapeutics|September 22, 2017
Risk and impact of herpes zoster on patients with diabetes: A population-based study, 2009-2014Cintia Muñoz-Quiles, Mónica López-Lacort, F Javier Ampudia-Blasco, et al.
Diabetes Research and Clinical Practice|June 22, 2019
How often patients on insulin therapy measure postprandial glycemia and modify insulin doses accordingly? From an on-line survey in insulin-treated diabetes patients in SpainEdurne Lecumberri Pascual, Cristina Tejera Pérez, Araceli Muñoz-Garach, et al.
European Journal of Clinical Investigation|March 21, 2022
Impact of COVID-19 lockdown on diabetes management and follow-up in a broad population in SpainAna Palanca, Carmen Quinones-Torrelo, Juan Girbés, et al.
Journal of Diabetes and Its Complications|January 13, 2021
Therapeutic inertia in patients with type 2 diabetes treated with non-insulin agentsF Javier Ampudia-Blasco, Ana Palanca, Jose Luis Trillo, et al.
Diabetes Technology & Therapeutics|September 26, 2012
Evaluation of a novel continuous glucose monitoring-based method for mealtime insulin dosing--the iBolus--in subjects with type 1 diabetes using continuous subcutaneous insulin infusion therapy: a randomized controlled trialPaolo Rossetti, F Javier Ampudia-Blasco, Alejandro Laguna, et al.
Pharmacoeconomics|June 28, 2006
Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in SpainArran T Shearer, Adrian Bagust, F Javier Ampudia-Blasco, et al.
Diabetes, Obesity & Metabolism|July 6, 2018
Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetesJulio Rosenstock, Yehuda Handelsman, Josep Vidal, et al.
Pageof 3